A panel of physicians and researchers is urging the U.S. Food and Drug Administration (FDA) to remove the strict black box warning on estrogen-containing hormone therapy used to treat menopause symptoms.
These treatments, widely prescribed to alleviate hot flashes, mood swings, and vaginal dryness, currently carry warnings about increased risks of stroke, blood clots, dementia, and breast cancer.
At a meeting led by Dr. Marty Makary, FDA Commissioner and a vocal advocate for hormone therapy, panelists argued that these warnings have frightened women away from a treatment with proven benefits—particularly when started within 10 years of menopause onset.
Dr. JoAnn V. Pinkerton of the University of Virginia Health System stated, “We are all begging the FDA: please remove the black box warning.”
Supporters point to observational studies and clinical experiences suggesting hormone therapy may reduce fatal heart attacks, prevent osteoporosis-related fractures, and even lower some cancer risks.
However, many experts argue that these claims lack support from randomized clinical trials, such as the Women’s Health Initiative (W.H.I.), which showed increased risks—especially when hormone therapy began later in life.
Critics, including longtime women’s health advocate Cindy Pearson, warned that the FDA panel was unbalanced, featuring mostly supporters of hormone therapy with pharmaceutical industry ties. She questioned the absence of public input and the lack of testimony from FDA scientists.
Despite the controversy, both sides agree that hormone therapy decisions should be individualized, considering age, health status, and delivery method (oral vs. transdermal or vaginal). But the call for the FDA to revisit its labeling underscores growing debate about how best to balance risks and benefits in women’s health.
Related topics:
Congress Targets Toxic Hair Products Risking Black Women’s Health
EU faces pressure to regulate sperm and egg donations
Menopause Hormone Therapy Enhances Obesity Drug’s Effectiveness in Women
